Americas Cancer Immunotherapy Market Scenario:
The Americas cancer immunotherapy market is expected to reach USD 118274.96 Million by 2030 at 13.80% CAGR during the forecast period 2022-2030.Cancer Immunotherapy is a treatment that uses a person’s immune system to fight the diseases. Some types of the cancer immunotherapies are often referred to as biologic therapies or biotherapies. The basic principle of cancer immunotherapy is to enhance a patient’s immune system to fight against cancer. This can be achieved by administrating various immune system components, such as synthesized immune proteins. In recent years,
cancer immunotherapy have been extensively exploited for the treatment of the different type cancers including breast, prostate, lung cancer, and others. Increasing prevalence of cancer is one of the major drivers for the Americas cancer immunotherapy market growth during the forecast period. The most commonly prevalent cancers in the U.S. include breast cancer, lung, bronchus cancer, and others. According to the National Cancer Institute in 2016, an estimated 1,685,210 new cases of cancer were diagnosed in the U.S. and approximately 595,690 people died due to cancer within the region. Moreover, growing geriatric population and rising healthcare expenditure will boost the market growth. Additionally, growing biotech and pharmaceutical industries fuels the market growth during the projected period. However, lack of awareness, restriction in therapeutics against different cancers and high cost for the treatment may restrain the market growth from 2022-2030.
A cancer treatment called cancer immunotherapy improves the immune system's capacity to combat cancer. Because it offers long-term cancer security, has fewer adverse reactions, and heals a wider range of cancers, this therapy is better than the outdated method. Cancer immunotherapy tackles the infectious organisms that may cause cancer by inducing the development of antibodies, which is essential for the immune system's upkeep. Cancer immunotherapy is a novel form of treatment, but it has demonstrated remarkable promise in recent years. Additionally, the market is anticipated to increase rapidly throughout the projected period because of the substantial increase in cancer cases and current therapies' negative effects. In North America, a sophisticated healthcare system and increased government programs that offer favorable reimbursement policies are the main forces behind market expansion.
The market is thus anticipated to develop profitably throughout the forecast period due to the rising cancer burden and escalating R&D in various areas of cancer. Cancer immunotherapy is utilized for managing a variety of malignancies, including head and neck, melanoma, prostate, breast, colorectal, lung, and more. Immunotherapy mobilizes the immune system by activating the target and causing a reaction that can destroy cancer cells. This is how it works: guiding the immune system onto targets particular to cancer. Therefore, some mesothelioma patients have effectively had their life expectancy prolonged in clinical trials using immunotherapy medications like Keytruda, which is what is predicted. Thus, during the projected period, the market is anticipated to rise due to newer medicines' improving efficacy and precision and their reduced adverse effects compared to conventional chemotherapy.
News:
A Fox Chase Cancer Center's Cancer Signaling and Microenvironment research program member recently received a $792,000 American Cancer Society scholarship grant to study cutting-edge lung cancer therapies. Prabha and colleagues will use the four-year award to create synthetic cellular targets for lung cancer immunotherapy. The novel practice of using medications, therapeutic vaccinations, antibodies, viruses, and cell-based therapies is known as immunotherapy. This procedure stimulates the body's immune system to recognize certain cancer cells and inhibit their growth.
Intended Audience
- Pharmaceutical Companies
- Biotechnological Institutes
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Market Research and Consulting Service Providers
Figure 1:- Americas cancer immunotherapy market share, by region
Sources: WHO, annual reports, press release, white paper, and company presentations
Segmentation
The Americas cancer immunotherapy market is segmented on the basis of cancer, therapeutics, and end users.
On the basis of the cancer, the Americas cancer immunotherapy market is segmented into lung cancer, prostate cancer, colorectal cancer, head & neck cancer, and others.
On the basis of the therapeutics, the Americas cancer immunotherapy market is segmented into monoclonal antibodies, immune checkpoint inhibitors, vaccines, non-specific cancer immunotherapies and adjuvants, and others. The monoclonal antibodies segment is sub segmented into naked monoclonal antibodies, conjugated monoclonal antibodies, chemolabeled antibodies, bispecific monoclonal antibodies, and others. The naked monoclonal antibodies segment, by monoclonal antibody segment, is father segmented into alemtuzumab, trastuzumab, and others. The immune checkpoint inhibitors segment is sub segmented into PD-1 inhibitors, PD-L1 inhibitors, and others. The PD-1 inhibitors segment, by immune checkpoint inhibitors, is sub segmented into pembrolizumab, nivolumab, and others. The PD-L1 inhibitors segment, by immune checkpoint inhibitors, is further segmented into atezolizumab, avelumab, and others. The non-specific cancer immunotherapies and adjuvants segment is sub segmented into cytokines, interleukins, and others.
On the basis of the end users, the Americas cancer immunotherapy market is segmented as hospitals & clinics, academic institutes, research organization, and others.
News:
In a recent early-stage trial, 50% of patients with pancreatic cancer who received a tailored mRNA cancer vaccine following surgery did not experience a tumor recurrence one and a half years later. The trial, presented in a research paper reported in Nature, had a tiny patient population of only 16; therefore, it will need to be repeated in more extensive investigations. In recent research, the same mRNA technology employed to produce the incredibly effective COVID vaccinations targeted the patient's tumor neoantigens. BioNTech, a company that collaborated with Pfizer to develop one of the COVID vaccines, made the experimental vaccinations that Balachandran and his associates utilized. Sixteen patients received vaccinations from the researchers. After removing the tumors surgically, they administered mRNA vaccinations customized for each patient's
Regional Analysis
On regional basis the Americas is divided into North America and Latin America. North America is sub segmented into U.S. and Canada. North America commands for the largest market share for the Americas cancer immunotherapy market due the presence of the U.S. within the region. This large share is also attributed due to the technologically advanced healthcare market in the region which is followed by high prevalence of cancer, increasing development in cancer immunotherapy treatment and rising per capita healthcare expenditure. Moreover, growing biotechnology, healthcare and life sciences sector within the region fuels the market growth regionally. The total number of the biotechnology industries in the U.S. increased from 2,763 in 2014 and reached 2,772 in 2015. Additionally, the abundance of state of the art laboratories in the U.S. is also facilitating the cancer immunotherapy market growth.
On the other hand, Latin America is the fastest growing region due to the presence of the developing economies within the region, rising healthcare expenditure and huge patient population.
Research Methodology
Sources: WHO, annual reports, press release, white paper, and company presentation
Key players for the Americas cancer immunotherapy market
Some of the major player in the Americas cancer immunotherapy market are Amgen Inc. (U.S.), AstraZeneca (U.K), F. Hoffmann-La Roche Ltd. (Switzerland), Bayer AG (Germany), Bristol-Myers Squibb Company (U.S.), Eli Lilly and Company (U.S.), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland), and others.
Report Attribute/Metric
|
Details
|
Market Size
|
USD 118274.96 Million
|
CAGR
|
13.80% (2022-2030)
|
Base Year
|
2021
|
Forecast Period
|
2022-2030
|
Historical Data
|
2020
|
Forecast Units
|
Value (USD Million)
|
Report Coverage
|
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
|
Segments Covered
|
Cancer, Therapeutics & End Users
|
Geographies Covered
|
Americas
|
Key Vendors
|
Amgen Inc. (U.S.), AstraZeneca (U.K), F. Hoffmann-La Roche Ltd. (Switzerland), Bayer AG (Germany), Bristol-Myers Squibb Company (U.S.), Eli Lilly and Company (U.S.), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland),
|
Key Market Opportunities
|
Rising cancer burden and escalating R&D in various areas of cancer
|
Key Market Drivers
|
Growing geriatric population and rising healthcare expenditure will boost the market growth
|
Cancer Immunotherapy Market Highlights: